WOLTERS-KLUWER
4.3.2024 09:01:31 CET | Business Wire | Press release
Wolters Kluwer Tax & Accounting (TAA) has launched CCH iFirm®, its award-winning cloud-based practice management and compliance software platform, in the U.K. The integrated and scalable platform is designed to help make tax and accountancy practices more efficient and productive.
“For over a decade, CCH iFirm has been driving impact globally for tax and accounting firms with its innovative technology and extensive capabilities, and we are excited to introduce this new platform to the U.K.,” said Bas Kniphorst, Executive Vice President and Managing Director, Wolters Kluwer TAA Europe. “Accounting firms are adopting technology solutions to help achieve greater business scalability, agility and resilience against the backdrop of an ever-evolving accountancy landscape. Wolters Kluwer CCH iFirm provides those capabilities through a unified platform with single sign-in.”
The new platform offers efficient and automated workflows and full integration and visibility across a range of accounting tools. It enables access to real-time data, while adhering to the top industry security standards. CCH iFirm thereby allows users to access new opportunities driven by data analysis, visualization, and reporting.
A leading cloud platform in the North America and Asia Pacific markets, the U.K. launch of CCH iFirm is the first in Europe. Existing users of Wolters Kluwer CCH Central, the on-premise accounting system in the U.K., can choose to make a one-off switch or a phased transition to the new platform.
Cloud brings new benefits
“CCH iFirm is a next-generation cloud platform which directly brings the reliability, expertise and innovative technology that Wolters Kluwer is famed for to our clients in the U.K.,” added Neil Parsons, Managing Director, Wolters Kluwer TAA U.K. “Significant changes to U.K. tax regulation are coming, particularly for sole traders and partnerships, so now is the perfect time for accounting firms to review and update their systems and move to the cloud.”
CCH iFirm integrates seamlessly into workflows, including with CCH Central. The new platform also syncs with popular accounting and productivity tools, creating a unified ecosystem designed to boost efficiency and productivity.
Adding functionality
The functionality of the CCH iFirm platform will expand in stages in the U.K. market, with several modules in the pipeline for rollout in the months ahead, including:
- CCH iFirm AML (Anti-Money Laundering) – facilitating AML checks on individuals direct from CCH Central, as a key part of the client-onboarding process.
- CCH iFirm Accounts Production – streamlining the accounts process, from data entry to online filing, enhancing compliance efficiency and profitability.
- CCH iFirm Personal Tax – helping accountants to prepare and submit personal tax returns for individual clients.
- CCH iFirm Validate – accelerating bank confirmations with cloud-based audit software, using blockchain technology.
CCH iFirm has been independently recognized for its innovations. Last year, for example, Wolters Kluwer TAA Asia Pacific won a Grand Globee at the 15th Annual 2023 Golden Bridge Innovation Awards in the Product Development Initiative of the Year category.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com and follow us on LinkedIn, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304177221/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom